Monte Rosa Therapeutics, Inc.
GLUEHeld by 5 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying5 funds opened new positions. Next phase2 readout (Oral MRT-2359): May 2026. Short interest: 20.6% of float.
Held by 5 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying5 funds opened new positions. Next phase2 readout (Oral MRT-2359): May 2026. Short interest: 20.6% of float.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.